
Fresenius Kabi Launches Otulfi, the 4th Biosimilar of Stelara to Become Available
Fresenius Kabi has launched the biosimilar Otulfi (ustekinumab-aauz)in the United States. Otulfi is a biosimilar that references Johnson & Johnson’s Stelara (ustekinumab). The FDA had approved Otulfi in September 2024 to treat patients six years of age …